Q-omics provides the consensus-scored MUC21 profile across patient tissues and cancer cell-line models. MUC21 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MUC21 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, MUC21 RNA expression shows 9,871 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, HNSC, and TGCT as cancer lineages where MUC21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC21 survival associations across molecular data types. MUC21 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC21 RNA expression–survival associations across cancer types. High MUC21 expression shows unfavorable associations in PAAD, KICH, DLBC, BRCA and LUSC, but favorable associations in ACC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MUC21 RNA expression.
This table summarizes MUC21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MUC21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC21 shows lower tumor expression in HNSC and LUSC and higher tumor expression in THCA, LUAD, UCEC and BRCA. The HNSC box plot shows higher MUC21 RNA expression in normal versus tumor tissue (log2 FC = −6.427, t-test p < 0.001).
This table shows molecular features associated with MUC21 in patient tissues and cancer cell lines. In patient samples, MUC21 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
